June 2007. Volume 3. Number 2

New vaccines against human papillomavirus in the prevention of cervical cancer

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

ED | Editorial

Author: Ruiz Contreras J1.
1Departamento de Enfermedades Infecciosas. Hospital Universitario 12 de Octubre. Madrid. España.
Correspondence: Jesús Ruiz Contreras. Email: evidencias@exlibrisediciones.com
Publication date: 01/06/2007

How to cite this article

Ruiz Contreras J. Las nuevas vacunas frente al papilomavirus humano en la prevención del cáncer de cérvix. Evid Pediatr. 2007;3:32.

ED | Editorial

Author: Ruiz Contreras J1.
1Departamento de Enfermedades Infecciosas. Hospital Universitario 12 de Octubre. Madrid. España.
Correspondence: Jesús Ruiz Contreras. Email: evidencias@exlibrisediciones.com
Publication date: 01/06/2007

How to cite this article

Ruiz Contreras J. Las nuevas vacunas frente al papilomavirus humano en la prevención del cáncer de cérvix. Evid Pediatr. 2007;3:32.

References

  1. World Health Organization. Human papillomavirus infection and cervical cancer. [en línea] [fecha de consulta: 29-V-2007]. Disponible en http://www.who.int/vaccine_research /diseases/hpv/en/
  2. Muñoz N, Bosch FX, De San José S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-27.
  3. Muñoz N, Castellsagué X, Berrington de González A, Gissmann L. HPV in the etiology of human cancer. Vaccine. 2006;24 Suppl 3;S1-10.
  4. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;24 Suppl 1:S4-15.
  5. Castellsagué X, Díaz M, De San José S, Muñoz N, Herrero R, Franceschi S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: Implication for screening and prevention. J Natl Cancer Inst. 2006;98:303-15.
  6. Bosch FX, Lorincz A, Muñoz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244-65.
  7. Walboomers JM; Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of cervical cancer worldwide. J Pathol. 1999;189:12-9.
  8. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157:218-26.
  9. Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJF, Vacarella S, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Researc on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005;366:991-8.
  10. Ho YF, Biermen R, Beardsley L, Chang CJ, Burk RD. Natural History of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423-8.
  11. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Updating the natural history of HPV and anogenital cancer. Vaccine. 2006; 24 Suppl 3: S42-S51.
  12. Molano M, Van den Brule A, Plummer M, Weiderpass E, Posso H, Aíslan a, et al. Determinats of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol. 2003;158:486-94.
  13. Moscicki AB, Shiboski S, Hills NK, Powell KJ, Jay N; Hanson EN, et al. Regression of low-grade intra-epitelial lesions in young women. Lancet. 2004;364:1678-83.
  14. Saslow D, Castle PE, Cox T, Davey DD, Einstein MH, Ferris DG, et al. American Cancer Society Guideline for Human Papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007;57:7-28.
  15. The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-27.
  16. Garland SM, Hernández-Avila M, Wheeler CM, Pérez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928-43.
  17. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet. 2004;364:1757-65.
  18. Joura EA, Leopdolter S, Hernández-Avila M, Wheeler CM, Pérez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6,11,16 and 18) L1 virus-like particle vaccine against high-grade vulvar and vaginal lesions: a combined analysis of three randomized clinical trials. Lancet. 2007;369:1693-702.
  19. Villa LL, Costa RLR, Petta CA, Andrade RP, Pavoneen J, Iversen OE. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95: 1-8.
  20. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247-55.
  21. Burchell AN, Winer RL, De San José S, Franco EL. Epidemiology and transmission dynamics of genital HIV infection. Vaccine. 2006;24 Suppl 3:S52-61.
  22. Weller SC, Stanberry LR. Estimating the population prevalence of HPV. JAMA. 2007;297:876-8.
  23. Wright TC, Van Damme P, Schmitt HJ, Meheus A. HPV vaccine introduction in industrialized countries. Vaccine. 2006;24 Suppl 3:S122-31.
  24. Burchell AN, Richardson H, Mahmud SM, Trottier H, Tellier P, Hanley J, et al. Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am J Epidemiol. 2006;163 534-43.
  25. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KED, Marchant CD, et al. Comparison of the immunogenicity and reactogenicicty of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in a male and female adolescents and young adult women. Pediatrics. 2006;118:2135-45.
  26. Garnett GP, Kim JJ, French K, Goldie SJ. Modelling the impact of HPV vaccines on cervical cancer and screening programs. Vaccine. 2006;24 Suppl 3:S178-86.
  27. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13:28-41.
  28. De San José S, Almirall R, Lloveras B, Font R, Díaz M, Muñoz I, et al. Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis. 2003;30:788-93.
  29. Schiffman M, Castle PE. The promise of global cervical-cancer prevention. N Engl J Med. 2005;353:2101-4.
  30. Centers for Disease Control and Prevention. Quadrivalent human papillomavirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2007;56/RR-2:1-24.
01/06/2007

Linked Comment